The invention relates to application of a biomarker composition in preparation of a
diagnostic reagent for fulminating
myocarditis and a
drug for fulminating
myocarditis, belonging to the field of
disease diagnostic reagents and drugs. The application is characterized in that the biomarker combination comprises
Siglec-5,
Siglec-5,
Siglec-5, Siglec-5, Siglec-5 and Siglec-5, the combination of biomarkers is further selected from the group consisting of sST2, PAI-1, Siglec-5, CD163, CD40, P-
Cadherin, CD14, and CTLA4, and the combination of biomarkers is selected from the group consisting of sST2, PAI-1, Siglec-5, CD163, CD40, P-
Cadherin, CD14, and The invention finds that the expression of the biomarker in the
plasma of a patient with the
outbreak myocarditis is increased, and proves that the biomarker plays a role in diagnosing the
outbreak myocarditis and the role of the biomarker as a
drug target in relieving and / or improving the
outbreak myocarditis, and the level of the biomarker can be detected, so that the application of the biomarker in the diagnosis of the outbreak myocarditis and the application of the biomarker in the treatment of the outbreak myocarditis can be realized. The biomarkers can be used for predicting and assisting in diagnosing the outbreak myocarditis or evaluating prognosis of the outbreak myocarditis, meanwhile, the level of the biomarkers is controlled through drugs, more intensified diagnosis and follow-up treatment can be carried out on diseases, and the biomarkers have huge clinical application value.